Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS )

30.08 +0.03 (+0.10%)
Official Closing Price Updated: 4:15 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,221
Open 30.22
Bid (Size) 30.08 (1)
Ask (Size) 30.14 (1)
Prev. Close 30.05
Today's Range 30.08 - 30.25
52wk Range 28.56 - 36.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence. 
Via Stocktwits

Performance

YTD
+3.08%
+3.08%
1 Month
+4.12%
+4.12%
3 Month
-1.02%
-1.02%
6 Month
-13.06%
-13.06%
1 Year
-8.60%
-8.60%

More News

Read More
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Via Benzinga
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Via Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
Via Benzinga
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
Via Talk Markets
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
Via Benzinga
Topics ETFs
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
Via Benzinga
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.